Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Japanese Phase 1 Study of Zandelisib (ME-401) in Relapsed/Refractory Indolent B-cell Non-Hodgkin Lymphoma and Roll-over Extension
jRCT2080224714Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zandelisib in non-Hodgkin lymphoma (NHL) (3 cohorts), sponsored by Kyowa Kirin. Primary endpoints: Dose-limiting toxicities and recommended dose and Safety in roll-over cohort. Started Jun 2019; status: completed.
02
Drugs
zandelisib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on jRCT2080224714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224714.